THE GENES, ENVIRONMENT, AND HOST IMMUNE RESPONSES IN THE ETIOLOGY OF SYSTEMIC LUPUS ERYTHEMATOSUS.

2004 ◽  
Vol 52 ◽  
pp. S258
Author(s):  
J B Harley ◽  
J A Kelly ◽  
M T McClain ◽  
J A James
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Immune Responses ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Host Immune Responses

scholarly journals The IL-2 Defect in Systemic Lupus Erythematosus Disease Has an Expansive Effect on Host Immunity

2010 ◽  
Vol 2010 ◽  
pp. 1-6 ◽  
Author(s):  
Linda A. Lieberman ◽  
George C. Tsokos
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Immune Responses ◽  
Lupus Erythematosus ◽  
Cell Function ◽  
Host Immunity ◽  
Systemic Lupus Erythematosus Disease ◽  
Systemic Lupus ◽  
Host Immune Responses ◽  
Activation Induced Cell Death ◽  
Immune Defects

IL-2 production is decreased in systemic lupus erythematosus (SLE) patients and affects T cell function and other aspects of host immunity. Transcription factors regulating IL-2 production behave aberrantly in SLE T cells. In addition to IL-2 dysregulation, other IL-2 family members (IL-15 and IL-21) are abnormally expressed in SLE. Decreased IL-2 production in SLE patients leads to many immune defects such as decreasedTregproduction, decreased activation-induced cell death (AICD), and decreased cytotoxicity. IL-2 deficiency results in systemic dysregulation of host immune responses in patients suffering from SLE disease.

Juvenile-onset systemic lupus erythematosus

2013 ◽  
pp. 948-956
Author(s):  
Louise Watson ◽  
Michael W. Beresford
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Family Involvement ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Juvenile Onset ◽  
Host Immune Responses ◽  
American College Of Rheumatology ◽  
Organ Manifestations ◽  
New Treatment ◽  
Onset Systemic Lupus Erythematosus

Paediatric or juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune condition, differing from the adult form in terms of severity, organ manifestations, and a less striking female predominance. The diagnosis relies on the adult-derived American College of Rheumatology SLE classification criteria. Genetic, autoantibody, and host immune responses, characteristic of this disease, result in a clinically heterogeneous phenotype. A proportion of paediatric SLE patients will have evidence of a genetic deficiency known to be associated with SLE, such as C1q deficiency, and screening for these is required. A challenging diagnosis to make in the younger age group, the management of JSLE compared to adult-onset SLE requires special consideration towards the significant long-term consequences of the disease and treatment toxicity, combined with an onset during a fundamental time with regards to growth and development. A comprehensive, multidisciplinary team approach to the management of JSLE is essential. With a more severe phenotype and limited comorbidities, patients with JSLE represent an invaluable opportunity for investigating the pathogenesis. To date, clinical trials informing interventions in JSLE are very limited and treatment choices rely on the outcome of adult trials. Patient and family involvement in research to improve outcomes and understanding is essential. New treatments, including biological therapies, are becoming available for clinical use and new treatment combinations have been used to induce and maintain clinical remission.

Paediatric-onset systemic lupus erythematosus

2013 ◽  
Author(s):  
Louise Watson ◽  
Michael W. Beresford
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Family Involvement ◽  
Lupus Erythematosus ◽  
Team Approach ◽  
Systemic Lupus ◽  
Host Immune Responses ◽  
American College Of Rheumatology ◽  
Organ Manifestations ◽  
New Treatments ◽  
Onset Systemic Lupus Erythematosus

Paediatric or juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune condition, differing from the adult form in terms of severity, organ manifestations, and a less striking female predominance. The diagnosis relies on the adult-derived American College of Rheumatology SLE classification criteria. Genetic, autoantibody, and host immune responses, characteristic of this disease, result in a clinically heterogeneous phenotype. A proportion of paediatric SLE patients will have evidence of a genetic deficiency known to be associated with SLE, such as C1q deficiency, and screening for these is required. A challenging diagnosis to make in the younger age group, the management of JSLE compared to adult-onset SLE requires special consideration towards the significant long-term consequences of the disease and treatment toxicity, combined with an onset during a fundamental time with regards to growth and development. A comprehensive, multidisciplinary team approach to the management of JSLE is essential. With a more severe phenotype and limited comorbidities, patients with JSLE represent an invaluable opportunity for investigating the pathogenesis. To date, clinical trials informing interventions in JSLE are very limited and treatment choices rely on the outcome of adult trials. Patient and family involvement in research to improve outcomes and understanding is essential. New treatments, including biological therapies, are becoming available for clinical use and new treatment combinations have been used to induce and maintain clinical remission.

scholarly journals Assessing the expression of immunosuppressive cytokines in the newly diagnosed systemic lupus Erythematosus patients: a focus on B cells

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Mitra Abbasifard ◽  
Zahra Kamiab ◽  
Mohammad Hasani ◽  
Amir Rahnama ◽  
Pooya Saeed-Askari ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
B Cells ◽  
Immune Responses ◽  
Lupus Erythematosus ◽  
Healthy Subjects ◽  
Serum Levels ◽  
Newly Diagnosed ◽  
Systemic Lupus ◽  
Moderate Disease ◽  
Immunosuppressive Cytokines

Abstract Background The immunosuppressive effects of regulatory B-cells (Bregs) and their immunosuppressive cytokines on immune responses in autoimmune disorders, mainly systemic lupus erythematosus (SLE), have been recently established. Therefore, the purpose of this article has been the exploration of the expressions of cytokines produced by B cells in newly diagnosed SLE patients. Results The findings demonstrated that the gene expression of IL-10, TGF-β, IL-35, PD-L1, and FasL was significantly up-regulated in SLE patients compared to healthy subjects (P < 0.05). Additionally, the results revealed that serum levels of IL-10, TGF-β, IL-35, PD-L1 were remarkably increased in patients with SLE compared to healthy subjects (P < 0.0001). However, serum levels of IL-10 and TGF-β decreased significantly with increasing SLEDAI score in studied patients (P < 0.05). Conclusion It was concluded that the release of anti-inflammatory cytokines, particularly IL-10 and TGF-β, might inhibit immune responses and autoreactive immune cells in a compensatory manner in SLE patients with mild to moderate disease activity.

Juvenile-onset systemic lupus erythematosus

2013 ◽  
pp. 948-956
Author(s):  
Louise Oni ◽  
Michael W. Beresford
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Family Involvement ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Juvenile Onset ◽  
Host Immune Responses ◽  
American College Of Rheumatology ◽  
Organ Manifestations ◽  
New Treatment ◽  
Onset Systemic Lupus Erythematosus

Paediatric or juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune condition, differing from the adult form in terms of severity, organ manifestations, and a less striking female predominance. The diagnosis relies on the adult-derived American College of Rheumatology SLE classification criteria. Genetic, autoantibody, and host immune responses, characteristic of this disease, result in a clinically heterogeneous phenotype. A proportion of paediatric SLE patients will have evidence of a genetic deficiency known to be associated with SLE, such as C1q deficiency, and screening for these is required. A challenging diagnosis to make in the younger age group, the management of JSLE compared to adult-onset SLE requires special consideration towards the significant long-term consequences of the disease and treatment toxicity, combined with an onset during a fundamental time with regards to growth and development. A comprehensive, multidisciplinary team approach to the management of JSLE is essential. With a more severe phenotype and limited comorbidities, patients with JSLE represent an invaluable opportunity for investigating the pathogenesis. To date, clinical trials informing interventions in JSLE are very limited and treatment choices rely on the outcome of adult trials. Patient and family involvement in research to improve outcomes and understanding is essential. New treatments, including biological therapies, are becoming available for clinical use and new treatment combinations have been used to induce and maintain clinical remission.

Sign in / Sign up

Export Citation Format

Share Document